April 17th 2025
A trial found magnetic resonance imaging correlated with physical function tests in patients with Duchenne muscular dystrophy.
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
February 12th 2025Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is priced at $3.2 million per dose, produced $821 million in net product revenue for the company in 2024.
Read More